In Zimbabwe, HPV vaccination was introduced nationally in 2018 targeting Grade 5 girls, with initial financing largely provided by Gavi and government co-financing covering procurement and delivery. To sustain the programme amid competing health priorities and fiscal constraints, Zimbabwe has pursued a multi-pronged financing and integration strategy. Key steps include embedding a dedicated HPV budget line within the national immunisation plan, leveraging an approved Gavi HSS top-up to cover delivery gaps, engaging district-level partners — including CHAI, EGPAF, Africa CDC, WHO, and UNICEF — to support service delivery in 33 high-burden zero-dose districts, and exploring public-private partnerships with immunisation-capable private sector actors. The nationwide adoption of the single-dose schedule has meaningfully reduced costs and cold chain requirements, eliminating the need to double school visit frequency and halving vaccine forecasting volumes. Strong coordination between the Ministry of Health and Child Care and the Ministry of Finance has enabled consistent co-financing payments; political will at the highest levels — including engagement from the First Lady — has further elevated HPV on the national agenda, with COVID-19 cited as a turning point that galvanised government commitment to immunisation more broadly. Integration with routine immunisation, school health days, HIV care platforms, and adolescent sexual and reproductive health services reduces incremental costs and broadens access. Remaining challenges include staff attrition, outreach logistics funding gaps, and the incomplete rollout of eLMIS for supply chain management. Recommendations to other countries emphasise early multi-ministerial engagement, dedicated budget lines, a resource mobilisation roadmap spanning short-term donor funding and long-term domestic financing, parliamentary advocacy, and building community ownership to ensure durability beyond external support.